Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free SCPS Stock Alerts

Scopus BioPharma (SCPS) Competitors

Scopus BioPharma logo
$0.0004 0.00 (0.00%)
As of 02:43 PM Eastern
Compare

SCPS vs. VINC, CARM, ARDS, TRVN, and NAVB

Should you be buying Scopus BioPharma stock or one of its competitors? The main competitors of Scopus BioPharma include Vincerx Pharma (VINC), Carisma Therapeutics (CARM), Aridis Pharmaceuticals (ARDS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Scopus BioPharma compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Scopus BioPharma Neutral

44.0% of Vincerx Pharma shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Scopus BioPharma N/A N/A N/A

Vincerx Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500.

Summary

Vincerx Pharma and Scopus BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

44.3% of Carisma Therapeutics shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scopus BioPharma has lower revenue, but higher earnings than Carisma Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Scopus BioPharma Neutral

Scopus BioPharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Scopus BioPharma N/A N/A N/A

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 199,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Carisma Therapeutics is more favorable than Scopus BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Scopus BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Carisma Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500.

Summary

Carisma Therapeutics beats Scopus BioPharma on 8 of the 11 factors compared between the two stocks.

How does Scopus BioPharma compare to Aridis Pharmaceuticals?

Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.03

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Aridis Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Scopus BioPharma has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 49.48, meaning that its stock price is 4,848% more volatile than the S&P 500.

Summary

Aridis Pharmaceuticals beats Scopus BioPharma on 3 of the 4 factors compared between the two stocks.

How does Scopus BioPharma compare to Trevena?

Trevena (NASDAQ:TRVN) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Scopus BioPharma has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Scopus BioPharma Neutral

13.6% of Trevena shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Scopus BioPharma N/A N/A N/A

Trevena has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500.

Summary

Trevena and Scopus BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Scopus BioPharma has lower revenue, but higher earnings than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Scopus BioPharma Neutral

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Scopus BioPharma N/A N/A N/A

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500.

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCPS vs. The Competition

Export
MetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$17K$889.47M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E RatioN/A1.7129.0428.47
Price / SalesN/A120.50476.6160.92
Price / CashN/A20.0727.6236.52
Price / BookN/A7.609.676.67
Net Income-$11.61M-$4.80M$3.55B$332.53M
7 Day PerformanceN/A-0.05%1.70%2.01%
1 Month PerformanceN/A5.50%5.62%9.19%
1 Year PerformanceN/A30.96%34.41%39.59%

Scopus BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$17KN/AN/A9
VINC
Vincerx Pharma
N/A$0.01
flat		N/AN/A$66KN/AN/A60
CARM
Carisma Therapeutics
2.3313 of 5 stars		$0.00
-16.7%		$1.00
+199,900.0%		N/A$21K$10.77M0.0020
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/A0.0030
TRVN
Trevena
N/A$0.01
flat		N/AN/A$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel